Commentary Open Access
Volume 3 | Issue 3 | DOI: https://doi.org/10.33696/AIDS.3.022
Brain Organoids: An Emerging Model System to Study HIV-1 Neuropathogenesis
Roberta S. dos Reis1, Velpandi Ayyavoo2,*
- 1Department of Neurobiology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 1526, United States
- 2Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh,PA 15260, , United States
Corresponding Author
Velpandi Ayyavoo, velpandi@pitt.edu
Received Date: July 07, 2021
Accepted Date: October 07, 2021
dos Reis RS, Ayyavoo V. Brain Organoids: An Emerging Model System to Study HIV-1 Neuropathogenesis. J AIDS HIV Treat. 2021; 3(3): 46-48.
Copyright: © 2021 dos Reis RS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Socio-Demographic Characteristics of Newly Diagnosed People Living with HIV Initiating Antiretroviral Treatment at the Adult Day Hospital of Bobo-Dioulasso Over a Five-year Period
Background: HIV infection is a major public health problem in sub-Saharan Africa, particularly in Burkina Faso. This study aimed to describe the socio-demographic characteristics of newly person living with HIV initiating antiretroviral treatment at the Adult Day Hospital of Bobo-Dioulasso over a five-year period. Materials and methods: A descriptive cross-sectional study was conducted from 1 January 2016 to 31 December 2020 at the Adult Day Hospital of Bobo-Dioulasso. People newly diagnosed with HIV after confirmatory testing and initiating antiretroviral therapy were included in this study.
CCR5 Inhibitors and HIV-1 Infection
Cellular components are attractive targets for antiviral therapy because they do not mutate as readily as do viral proteins do [1-3]. The identification of CCR5 as an HIV-1 coreceptor [4-7], facilitated by the discovery of the antiviral activities of CCR5 ligand ?-chemokines [8], resulted in the development of new viral entry inhibitors to block CCR5 binding, including both- small molecules and CCR5 antibodies
Recent Progress in Preclinical HIV-1 Vaccine Research
Since isolation in humans in 1983 [1,2], HIV-1 has developed into a global pandemic. But an effective HIV-1 vaccine has not been succeeded despite multiple human vaccine trials performed [3,4]. Challenges to an effective vaccine arise from intrinsic virological and immunological features of HIV-1 [3-8].
Anti-HIV-1 Activity of Crocodylus mindorensis (Philippine Crocodile) Serum in Cell-free and Cell-associated Virus Interactions to Human Peripheral Blood Mononuclear Cells
Highly-Active Antiretroviral Therapy (HAART) is the recommended treatment and management strategy for HIV infection. Although the existing antiretroviral drugs are indispensably significant in improving the quality and extending the lives of HIV/ AIDS individuals, the drugs still have many limitations including development of resistance, production of toxicity, and their limited availability.
HIV-1 Treatment Failure among Population Taking Antiretroviral Therapy in Ethiopia
For more than 35 years, the world has grappled with an AIDS epidemic that has claimed an estimated 35.0 million [28.9 million-41.5 million] lives and at its peak threatened global stability and security.